Anti-Cullin-5 (CUL5) Antibody

Control
Human heart tissue lysate

Evaluated by Western Blotting in human heart tissue lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected Cullin-5 in 10 µg of human heart tissue lysate.

Detect Cullin using this rabbit polyclonal antibody, Anti-Cullin-5 (CUL5) Antibody validated for use in western blotting & IHC.

Immunohistochemistry Analysis: A 1:2,000 dilution from a representative lot detected Cullin-5 in human placenta and human testis tissue.

Research Category
Neuroscience

Research Sub Category
Developmental Signaling

Other homologies: Feline (93% sequence homology) and Mouse and Rat (87% sequence homology).

This antibody recognizes Cullin-5 near the N-Terminus.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

CUL-5/VACM-1 (cullin-5, vasopressin-activated calcium mobilizing receptor 1) is one component of the ECS (elongin B/C-cul2/cul5-SOCS box protein) complex that forms an E3 ubiquitin ligase that covalently binds ubiquitin to proteins targeted for degradation via the proteasome. CUL-5 is ubiquitously expressed in the central nervous system and in many peripheral organs. Human immunodeficiency virus-1 (HIV-1) protein Vif forms a Skp1-cullin-F-box (SCF)-like complex with CUL-5/VACM-1 and Elongins B and C. The ability of Vif to suppress the antiviral activity of APOBEC3G, which induces hypermutations in newly synthesized viral DNA, is specifically dependent on CUL-5-SCF function, as it allows Vif to interact with APOBEC3G and induce its ubiquitination and degradation. The CUL-5-SCF pathway used by Vif is thus a potential target for antiviral development. CUL-5/VACM-1 inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways. In human tissues expression in kidney, brain, heart, placenta, and skeletal muscle is observed. CUL-5/VACM-1 is also expressed in both breast epithelial cells and breast cancer cells. Decreased expression of CUL-5/VACM-1 may play a role in breast tumorigenesis. Further evidence for this finding is observed in T47D breast cancer cells in which overexpression of CUL-5/VACM-1 significantly attenuates cellular proliferation and MAPK phosphorylation when compared to control cells.

~90 kDa observed. Neddylation of Cullin-5 at a.a. 724 with NEDD8 results in a 10 kDa increase in molecular weight (Hori. T., et al. (1999). Oncogene. 18(48):6829-6834).

Epitope: Near N-Terminus

KLH-conjugated linear peptide corresponding to human Cullin-5 near the Near N-Terminus.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Replaces: AB10622

Antigen Affinity Purified

Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.